|
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC report, Drugs for the Elderly: Changing Products and Markets, is designed to provide the reader with a background of the elderly
population in the United States, growth of this population in the past and future, diseases and conditions affecting the elderly and drugs used with
special considerations when treating elderly patients. This study discusses prescription drugs by therapeutic categories in areas that elderly drug
use is a major contribution to revenues. It also displays areas where drug research, development and successful marketing strategies may be beneficial
to the pharmaceutical drug manufacturer including areas where the market is overwhelmed with product choices and market penetration may be difficult.
REASONS FOR DOING THE STUDY
The U.S. elderly population is growing at a rate of 1.5% per year and will reach 37.4 million by the year 2007. The study outlines areas that
provide an opportunity for prescription drug growth and development of drugs that cater to the over 65 population. As the Baby Boomer generation
continues to reach this age group, the need for new and improved drugs is a concern to consumers, health care providers and pharmaceutical
manufacturers around the globe.
SCOPE AND FORMAT
This BCC report is designed to be a helpful business tool to provide a thorough evaluation of the U.S. prescription drug market for the elderly.
The geographic scope of the report is the United States. The report identifies prescription pharmaceuticals in the various areas of concern for the
elderly population. A brief explanation of the various areas of concern is discussed including incidence, mortality, treatments, market size and
participants. The report covers the elderly position in the U.S. pharmaceutical market and its relationship to the healthcare industry in general.
Within the Drugs for the Elderly: Changing Products and Markets report, covered categories include:
- Anti-infective drugs
- Cardiovascular drugs and blood modifiers
- Central nervous system drugs
- Dermatologic and sensory organ drugs
- Gastrointestinal drugs
- Kidney and urinary system drugs
- Malignant and immune disease drugs
- Metabolic, endocrine, and hormone drugs
- Respiratory drugs
- Sexual dysfunction and genital organ drugs.
All segments are further extrapolated into specific drugs, which are discussed in detail. Each segment measures current and forecasted markets and
identifies market drivers and potential competitors.
METHODOLOGY
The information obtained for this BCC report is based on in-depth first-hand interviews with primary executives, product managers, and clinical
specialists in the area of drugs for the elderly. Background information was based on data obtained from various government, business, medical
journal, and trade magazines. Key information from published literature was used to conduct interviews with over 75 industry participants to confirm
conclusions contained in the report. Interviews were also used to validate market size and market share estimates, as well as formulating market
forecasts.
All market data pertain to the U.S. market at the manufacturer level. Data are expressed in current U.S. dollars. The base year of the report was
2002. Historical data are provided for 2000 and 2001 and forecast data are provided for 2007. Historical, base year and forecast data are provided for
each market segment in the report. Market shares are provided for each market segment for the 2002 base year. | 
View Cart
